Lumbrokinase/paclitaxel nanoparticle complex: potential therapeutic applications in bladder cancer

Hu, Bo; Yan, Yan; Tong, Fei; Xu, Long; Zhu, Jia; Xu, Guangtao; Shen, Ruilin

doi:10.2147/ijn.s166438

Cited by 15 publications

(5 citation statements)

References 53 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hu et al skillfully used block copolymer PEG-b-(PELG-g-(PZLL-r-PLL)) as a nanocarrier to deliver lumbrokinase (LK) with PTX and avoided the great toxicity and ensure sustained release in bladder. In addition, LK/PTX/PEG- b-(PELG-g-(PZLL-r-PLL)) successfully suppressed bladder tumor growth and induced bladder cancer cell death both in vivo and in vitro [ 84 ].…”

Section: Nanotechnology In Treatmentmentioning

confidence: 99%

State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer

et al. 2022

View full text Add to dashboard Cite

Bladder cancer is a common malignant tumor of the urinary system. Cystoscopy, urine cytology, and CT are the routine diagnostic methods. However, there are some problems such as low sensitivity and difficulty in staging, which must be urgently supplemented by novel diagnostic methods. Surgery, intravesical instillation, systemic chemotherapy, and radiotherapy are the main clinical treatments for bladder cancer. It is difficult for conventional treatment to deal with tumor recurrence, progression and drug resistance. In addition, the treatment agents usually have the defects of poor specific distribution ability to target tumor tissues and side effects. The rapid development of nanomedicine has brought hope for the treatment of bladder cancer in reducing side effects, enhancing tumor inhibition effects, and anti-drug resistance. Overall, we review the new progression of nano-platforms in the diagnosis and treatment of bladder cancer.

show abstract

Section: Nanotechnology In Treatmentmentioning

confidence: 99%

State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…PTX with hydrophobicity property is able to combine PZLL through hydrophobic interaction, thereby enhancement of the half-life and bioavailability of the drugs could be developed via the sustained release and enhancement of tumor site enrichment through passive targeting. They found that (PEG-b-(PELG-g-(PZLL-r-PLL)) polymers prolonged the half-life and bioactivity of LK and PTX in Sprague-Dawley rats [ 155 ]. Tao et al developed increasing delivery efficiency with utilizing different degree of cholesterol substituted pullulan polymer (CHPS).…”

Section: Applications Of Nanomaterials In Treatment Of Bcmentioning

confidence: 99%

Nanotechnology in Bladder Cancer: Diagnosis and Treatment

Barani

Hosseinikhah

Rahdar

et al. 2021

Cancers

View full text Add to dashboard Cite

Bladder cancer (BC) is the second most common cancer of the urinary tract in men and the fourth most common cancer in women, and its incidence rises with age. There are many conventional methods for diagnosis and treatment of BC. There are some current biomarkers and clinical tests for the diagnosis and treatment of BC. For example, radiotherapy combined with chemotherapy and surgical, but residual tumor cells mostly cause tumor recurrence. In addition, chemotherapy after transurethral resection causes high side effects, and lack of selectivity, and low sensitivity in sensing. Therefore, it is essential to improve new procedures for the diagnosis and treatment of BC. Nanotechnology has recently sparked an interest in a variety of areas, including medicine, chemistry, physics, and biology. Nanoparticles (NP) have been used in tumor therapies as appropriate tools for enhancing drug delivery efficacy and enabling therapeutic performance. It is noteworthy, nanomaterial could be reduced the limitation of conventional cancer diagnosis and treatments. Since, the major disadvantages of therapeutic drugs are their insolubility in an aqueous solvent, for instance, paclitaxel (PTX) is one of the important therapeutic agents utilized to treating BC, due to its ability to prevent cancer cell growth. However, its major problem is the poor solubility, which has confirmed to be a challenge when improving stable formulations for BC treatment. In order to reduce this challenge, anti-cancer drugs can be loaded into NPs that can improve water solubility. In our review, we state several nanosystem, which can effective and useful for the diagnosis, treatment of BC. We investigate the function of metal NPs, polymeric NPs, liposomes, and exosomes accompanied therapeutic agents for BC Therapy, and then focused on the potential of nanotechnology to improve conventional approaches in sensing.

show abstract

“…Its further use to inhibit tumor survival might also be taken into consideration, which means whether lumbrokinase treatment is beneficial for the outcome of tumor patients, especially NSCLC patients, deserves exploration. Several studies have indicated that lumbrokinase could inhibit the growth and metastasis of bladder cancer, gastric cancer, and hepatoma cells in vitro and in animal models [33], although it is still in the early stages of research. Furthermore, considering that the anticoagulant effect of lumbrokinase might possibly compensate for the risk of thrombosis caused by bevacizumab treatment in NSCLC patients, and its natural source, low toxicity, and certain anti-tumor activity might also possibly neutralize the toxic and side effects of chemotherapeutics and delay or weaken the emergence and development of chemoresistance, the potential of the combined treatment strategy including lumbrokinase and bevacizumab or lumbrokinase and chemotherapy might be highlighted for NSCLC patients.…”

Section: Introductionmentioning

confidence: 99%

Lumbrokinase Extracted from Earthworms Synergizes with Bevacizumab and Chemotherapeutics in Treating Non-Small Cell Lung Cancer by Targeted Inactivation of BPTF/VEGF and NF-κB/COX-2 Signaling

Hua,

Guo,

Dai

et al. 2024

Biomolecules

View full text Add to dashboard Cite

As a kind of proteolytic enzyme extracted from earthworms, lumbrokinase has been used as an antithrombotic drug clinically. Nevertheless, its potential in anti-cancer, especially in anti-non-small cell lung cancer (NSCLC), as a single form of treatment or in combination with other therapies, is still poorly understood. In this study, we explored the anti-tumor role and the responsive molecular mechanisms of lumbrokinase in suppressing tumor angiogenesis and chemoresistance development in NSCLC and its clinical potential in combination with bevacizumab and chemotherapeutics. Lumbrokinase was found to inhibit cell proliferation in a concentration-dependent manner and caused metastasis suppression and apoptosis induction to varying degrees in NSCLC cells. Lumbrokinase enhanced the anti-angiogenesis efficiency of bevacizumab by down-regulating BPTF expression, decreasing its anchoring at the VEGF promoter region and subsequent VEGF expression and secretion. Furthermore, lumbrokinase treatment reduced IC50 values of chemotherapeutics and improved their cytotoxicity in parental and chemo-resistant NSCLC cells via inactivating the NF-κB pathway, inhibiting the expression of COX-2 and subsequent secretion of PGE2. LPS-induced NF-κB activation reversed its inhibition on NSCLC cell proliferation and its synergy with chemotherapeutic cytotoxicity, while COX-2 inhibitor celecoxib treatment boosted such effects. Lumbrokinase combined with bevacizumab, paclitaxel, or vincristine inhibited the xenograft growth of NSCLC cells in mice more significantly than a single treatment. In conclusion, lumbrokinase inhibited NSCLC survival and sensitized NSCLC cells to bevacizumab or chemotherapeutics treatment by targeted down-regulation of BPTF/VEGF signaling and inactivation of NF-κB/COX-2 signaling, respectively. The combinational applications of lumbrokinase with bevacizumab or chemotherapeutics are expected to be developed as promising candidate therapeutic strategies to improve the efficacy of the original monotherapy in anti-NSCLC.

show abstract

Lumbrokinase/paclitaxel nanoparticle complex: potential therapeutic applications in bladder cancer

Cited by 15 publications

References 53 publications

State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer

State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer

Nanotechnology in Bladder Cancer: Diagnosis and Treatment

Lumbrokinase Extracted from Earthworms Synergizes with Bevacizumab and Chemotherapeutics in Treating Non-Small Cell Lung Cancer by Targeted Inactivation of BPTF/VEGF and NF-κB/COX-2 Signaling

Contact Info

Product

Resources

About